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Abstract. A new line of dystrophic mdx mice on the DBA/2J (D2) background has emerged as a candidate
to study the efficacy of therapeutic approaches for Duchenne muscular dystrophy (DMD). These mice harbor
genetic polymorphisms that appear to increase the severity of the dystropathology, with disease modifiers that
also occur in DMD patients, making them attractive for efficacy studies and drug development. This workshop
aimed at collecting and consolidating available data on the pathological features and the natural history of these
new D2/mdx mice, for comparison with classic mdx mice and controls, and to identify gaps in information and
their potential value. The overall aim is to establish guidance on how to best use the D2/mdx mouse model in
preclinical studies.
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BACKGROUND
Duchenne muscular dystrophy (DMD) is a
severely progressive muscle-wasting disease, caused
by mutations in the DMD gene, which abolish dys-
trophin production. Lacking this protein, muscle
fibers are sensitive to contraction-induced damage,
resulting in chronic inflammation, impaired regener-
ation and replacement of muscle tissue by fibrotic
and adipose tissues. Patients become wheelchair-
dependent around the age of 12, require assisted
ventilation around the age of 20 and often die pre-
maturely in the 2nd to 4th decade of life due to
cardiac or respiratory complications. Currently, many
therapeutic approaches are in preclinical and clinical
development, and aim to restore the missing pro-
tein, to improve regeneration and muscle mass and/or
reduce inflammation and fibrosis. However, thus
far translating findings from preclinical models to
patients is challenging, where findings in mouse mod-
els are often not fully recapitulated in DMD patients.
As we consider the body of existing data on two key
(DMD) mouse models – the classic C57BL/10ScSn-
Dmdmdx /J (Bl10/mdx) [1] and the promising new
D2.B10-Dmdmdx /J (D2/mdx) model [2, 3] – a need
exists to clarify the field’s present understanding of
best practices in preclinical research using these two
models, in particular when to use which model and
which outcome measures to select, depending on the
objectives. Charley’s Fund, a foundation dedicated
to accelerating the development of life-saving treat-
ments for DMD, engaged leading experts from both
academia and industry to establish a collaborative
effort to address this issue. The founding objectives
set forth included: 1) help establish a grounding per-
spective on the present state of the data; 2) align on
best practices for selecting the best model for various
types of interventions and appropriate outcome mea-
sures to assess therapeutic effects covering muscle
function and pathology; 3) ensure that natural history
of the new D2/mdx model is collected without gaps;
and 4) help establish more rigorous selection criteria
designed to improve decisions on when to graduate a
therapy to human clinical trials.
It was acknowledged that success in achieving
these objectives would require significant, ongoing
work from the parties involved. As a key ground-
ing step, however, a 1.5-day key stakeholder meeting
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entitled “Of Mice and Measures: A Project to
Improve How We Advance DMD Therapies to the
Clinic” was organized in Paris, France on 2–3 Octo-
ber 2017 to discuss the available science around this
topic and prioritize action steps to move the field
forward to improved therapeutic testing.
PRE-WORKSHOP PREPARATION AND
DATA COLLECTION
Charley’s Fund engaged several leading experts
to facilitate this project in 2016, creating a Scien-
tific Organizing Committee responsible for directing
the project, including this workshop, in early 2017.
This committee included Charley’s Fund person-
nel, academic and industry individuals who directly
perform or oversee preclinical testing in their own
laboratories, and a statistician experienced in han-
dling complex datasets. Over the course of nearly a
year leading up to the workshop itself, the members
of the committee convened frequently by phone and
email.
The goals of this project required the collec-
tion and organization of functional, histological and
biomarker data on the Bl10/mdx1 and D2/mdx murine
models from several different sources. D2/mdx mice
that were backcrossed for 5 generations (3) and inter-
crossed for more than 9 generations were used for
most of the studies. In order to allow consolidation
and comparison of data from different sources, a data
collection template was developed and sent to each
contributor. This template described the format of
the data required, standardized the units of collec-
tion as much as possible, and provided directions to
ensure that each contributor provided all necessary
information.
Over a period of 3 months, data templates were
populated by 10 contributors out of the several groups
contacted by Charley’s Fund that work with D2/mdx.
These included seven academic groups, two private
industry groups, and one non-profit organization. The
data included over 230 different outcome parame-
ters collected on 650 individual mice and yielding
nearly 18,000 individual data points for comparison
(see Table 1).
Working groups were organized to assess the out-
comes according to a few specialized areas and
develop findings to be presented for discussion at
the workshop. These working groups included genet-
1 Of 650 individual mice, 29 mdx mice had a C57BL/6 back-
ground.
ics, natural history of disease, histological markers,
biomarkers, behavior and skeletal muscle strength
outcomes, respiratory assessments, cardiac assess-
ments, and therapeutic responses. Multiple rounds
of analysis and discussion were done within each
working group prior to the October 2017 meeting.
Based on the goals set out at the beginning of
the project, several different statistical analyses were
planned. These included an observational description
of the data to assess the present state of the informa-
tion, comparisons between the classic Bl10/mdx and
the new D2/mdx model to define outcomes most sen-
sitive to the disease model, and comparisons between
therapeutic interventions to define outcomes most
useful in the evaluation of future therapies. This ambi-
tious project benefitted from the overall coordination
of the processes by dedicated people from Charley’s
Fund, the organized way in which the data were col-
lected, and having the statistical analysis for each
working group performed by the same statistician.
Many statistical models were used in the analysis
of these data and they are not discussed in detail here,
however, a few overarching principles were followed.
Descriptive statistics were presented collectively and
stratified by mouse strain and by data source. For
some outcomes collected on mice over a wide range
of ages, descriptive statistics were also stratified by
age. For inferential statistics, normality of all con-
tinuous outcomes was assessed before analysis and
data transformations were applied where applicable.
If the normality assumption could not be met, non-
parametric statistical tests were used. All analyses
of repeated assessments made on the same mouse
accounted for the dependence of the assessments
using mixed effects linear regression models.
Several general observations were apparent from
the start.
1. Many outcomes were collected from only one
source, making the assessment of inter-laboratory
reliability not yet possible for those outcomes.
Many laboratories focus on one particular area
of assessment, thus the outcomes submitted by
each source primarily involved one body system
and these differed between sources.
2. Several outcomes were assessed by multiple
sources but different methodologies were used for
collection. This was particularly true with muscle
strength assessments, where data collection was
done in vivo and ex vivo by different sources.
3. For behavioral outcomes the variability
was higher, indicating the need to consider
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Table 1
Working groups and number of data points collected for this study
Strain measured
Class of Readout Data Age range Bl10/ Bl10/ D2/ D2/ Contributors
readout Data (weeks) mdx wt mdx wt
Natural History
Lean and fat mass 394 6–12 * * Pfizer
Body weight 2800 4–65 * * * * Aartsma-Rus, De Luca, Duan,
Jax, Nagaraju, Pfizer, Sarepta,
Spencer
Tissue weights (excluding heart) 2135 4–65 * * * * Aartsma-Rus, De Luca, Duan,
Nagaraju, Pfizer
Tibia length 18 23–30 * * Duan
Functional
Wheel (voluntary and exhaustion) 318 8–58 * * * * De Luca, Nagaraju
Open field (all assessments)1 376 8–65 * * * Jax, Nagaraju, Spencer
Grip strength (incl. normalized &
hang test)
4142 4–65 * * * * Aartsma-Rus, De Luca, Jax,
Nagaraju, Sarepta, Spencer
Rotarod 612 6–65 * * * * Jax, Nagaraju, Sarepta
Hindlimb sonography2 72 28 * * * * De Luca
Force (all muscles, all conditions) 1816 8–65 * * * * De Luca, Duan, Jax, Nagaraju,
Pfizer
Cardiac Functional assessments
3 761 16–58 * * De Luca, Duan, Nagaraju
Size/weight assessments 288 4–65 * * Aartsma-Rus, Duan, Nagaraju
Histology All assessments4 1240 8–78 * * Aartsma-Rus, Duan, Jax,
Nagaraju, Yokata
Respiratory All assessments 1174 4–34 * * Aartsma-Rus, Spencer
Therapeutics Gene expression in response to
exon skipping
71 13 * * Aartsma-Rus
Biomarkers
CK 574 8–64 * * * * Aartsma-Rus, De Luca, Jax,
Nagaraju
LDH 76 9–64 * * * * De Luca
Serum biomarkers5 37 13–36 * * Duan, Nagaraju
Dystrophin level 12 13 * * Aartsma-Rus
Gene expression6 939 10–34 * * * * Aartsma-Rus, Jax
1Includes open field distance run, Digiscan measurements, and # of rearings. 2Includes volume and % vascularization. 3Shortening fraction,
ejection fraction, stroke volume, and cardiac output also measured in Bl10 mice. 4Fiber area, fibrosis area, and % calcification also measured
in Bl10 mice. 5Includes WBCs, macrophages, and neutrophils. 6Gene expression values from 12 genes in two different tissues (gastrocnemius
and diaphragm).
operator-related issues and the need to follow
standard operating procedures.
4. The age of the mice from different sources varied
considerably making direct comparisons between
sources problematic.
5. Data were not generated specifically for this
project. Rather it was collected by each source
from its own research studies. Thus, the major-
ity of data collected were from mice included as
part of drug studies but untreated with any active
agent. This included both mice that had received
a vehicle or sham treatment and mice that were
completely untreated. The similarity of these two
groups is unknown.
Given all of these observations, we generated
descriptive statistics for all outcomes and performed
inferential statistical analysis where appropriate.
The working groups generated presentations which
included the results, notable findings and discussion
points; these were presented to the group of key stake-
holders at the workshop. After each working group
presentation, a description of known issues, iden-
tification of additional questions, and conclusions
based on the data presented were discussed in depth.
The highlights of each working group are described
below.
GENETICS OF THE D2/mdx MODEL
The D2/mdx carries the mdx mutation on the
DBA/2J genetic background, which poses several
advantages over the Bl10/mdx model. Several aspects
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of the pathology match DMD patients’ pathol-
ogy, like the increased EBD-membrane permeability,
fibrosis and TGF- signaling, the impaired satel-
lite cell activation and reduced regeneration [3]. Full
genotyping of the D2/mdx background is still pend-
ing. However, it is already known that polymorphisms
on the genes for latent TGF--binding protein 4
(Ltbp4) and annexin A6 (Anxa6) [4–6] respectively
account for 40% and 7% of the phenotype in a mouse
model for limb girdle muscular dystrophy type 2C
(Sgcg) mice on a DBA2/J genetic background. The
other 50% is unknown. The Ltbp4 and Anxa6 poly-
morphisms act in concert to modify muscle repair
[7] and are thought to underlie the increased fibro-
sis and impaired regeneration in the D2/mdx model,
respectively, while a variation in the Abcc6 gene is
responsible for the observed calcifications. Notably,
the Ltbp4 gene is also a modifier of human mus-
cular dystrophy [8]. During breeding, genetic drift
needs to be taken into account. The Jackson Labora-
tory advises refreshing in-house colonies every third
generation.
While some natural history studies have been ini-
tiated with these mice, a lot of additional work is
required to obtain a detailed picture of the natural
history of disease. Furthermore, to determine the use-
fulness of the D2/mdx model for DMD therapeutic
developments, the translatability of outcomes from
mouse to human needs to be established.
It is important to be aware that wild type DBA/2J
mice often have cardiac fibrosis and calcification,
which poses challenges when using the D2/mdx
model to study cardiac pathology, because it is not
clear to which extent these are related to the lack of
dystrophin or due to the DBA/2J background.
NATURAL HISTORY OF D2/mdx MICE
Life spans for animal models with dystrophin loss
have been compared [9]. For DMD patients, life span
has improved considerably in the last decade, due
to improved pulmonary and cardiac care. For the
D2/mdx life span, data up to 60 weeks of age are
available and more is being collected.
Data on body weight of D2/mdx mice were col-
lected from eight different laboratories. Body weights
of D2/mdxmice were clearly lower than for Bl10/mdx
and always lower than the wild type DBA/2J mice,
in contrast with Bl10/mdx mice that tended to weigh
more than their wild type strain (C57Bl/10Scsn) at
all ages (Fig. 1). There was a difference of up to 10
Fig. 1. Body weight distribution over age in Bl10/mdx (blue line),
Bl10/wt (red line), D2/mdx (green line), D2/wt (black line). Data
were collected from 8 labs.
grams between the body weights of D2/mdx from dif-
ferent sources that was seen with mixed genders as
well as within males only. This variability may be due
to husbandry, genetic drift or transportation stress if
mice were purchased.
Skeletal muscle atrophy was observed in D2/mdx
mice compared to DBA/2J wild types, which
increased with age and was more apparent in big-
ger muscles than in small ones. D2/mdx mice had
less fat and lean mass than DBA/2J wild types.
Interestingly, spleen weight was higher in mdx as
compared to wild type for both strains up to 30 weeks.
Increased spleen weight probably reflects chronic
muscle inflammation and muscle degeneration in
these mice. Normalized heart weights were larger
from a young age onwards in D2/mdx mice compared
to DBA/2J wild type, and differences became more
pronounced with increasing age. Functional heart
deficits appeared earlier in D2/mdx than in Bl10/mdx
and could possibly relate to the calcification process
observed in all DBA/2J mice.
Serum creatine kinase (CK) levels decreased with
age in both mdx mouse strains, similarly to what is
observed in DMD patients [10]. This age-dependent
decrease needs to be taken into account when CK is
used to monitor the efficacy of a therapy that helps
maintain muscle mass.
The forelimb grip strength normalized to body
weight was higher in D2/mdx compared with
Bl10/mdx. This may be due to the lower body weight
observed in D2/mdx mice. The values of normal-
ized grip strength tended to remain stable with age,
and the difference to wild type was evident only for
the Bl10 background. In DMD children, the loss of
grip strength is more prominent than in mdx mice.
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By contrast, the specific force, measured on the
EDL muscle, was decreased in both mdx strains as
compared to wild type, and Bl10/mdx specific force
remains relatively constant with age although signif-
icantly lower than their wild type counterparts.
In summary, a certain variability was detected by
comparing measurements from different labs, which
may, next to husbandry conditions, be due to micro-
biota composition and nutritional aspects, instrument
calibration and the genetic drift that occurs in the in-
house colonies. In addition, the age range of D2/mdx
mice likely to be influenced by treatments could not
yet be defined.
HISTOLOGICAL MEASURES
Histology data were in general difficult to com-
pare because labs collected different data and because
the muscle pathology tended to be localized. The
available data revealed that D2/mdx mice had fewer
centronucleated myofibers than Bl6/mdx between
10–80 weeks of ages and that revertant fibers
increased with age in Bl6/mdx but not in D2/mdx
mice [11]. Both these parameters indicate less regen-
eration in D2/mdx compared with Bl6/mdx muscles
and this was further supported by the D2/mdx mice
having fewer eMHC positive fibers and BrdU positive
nuclei. Terry Partridge presented data from his lab on
BrdU incorporation as a measure of myogenic activ-
ity and showed that muscles D2/mdx began, like the
original Bl10mdx, to degenerate at 3 weeks of age,
but did not start regenerating significantly over the
subsequent two weeks, while Bl10/mdx had replaced
20–25% of muscle in the same period.
Fibrosis in D2/mdx was found to occur earlier in
heart tissue (at 8 vs 36–40 weeks) and at higher
levels in skeletal muscle tissue (for instance 20%
vs 10% of total area at 10 weeks in the gastrocne-
mius) compared to Bl10/mdx. Calcification was more
prominent in D2/mdx mice than in Bl10/mdx mice
and both wild type strains. It affected skeletal mus-
cles and heart to different extents and decreased in
severity with age. The calcification was especially
pronounced in the diaphragm of 8-week old D2/mdx
mice, but reduced in area in adult (34 weeks) mice.
This calcification at an early age (8 weeks) needs to
be taken into account when measuring muscle func-
tion, but also when staining tissues, since it sequesters
dyes and antibodies, resulting in very bright, a-
specific staining of calcified areas. A longitudinal
study and a better understanding of this pathological
event are needed. It was observed that calcification
can be local and requires quantitation of the whole
muscle cross-sectional area. Calcification does not
occur in human dystrophic muscles, and over time
fibrosis is replaced by adiposis in Duchenne mus-
cles. In the first report describing D2/mdx mice,
mice exhibit increased fat accumulation compared
with B10/mdx mice [2]. However, no fat infiltration
was observed in D2/mdx muscles in the frame of
this work.
It is not known whether the reduced regeneration
is due to an intrinsic problem of the satellite cells or
to the elevated TGF levels, or simply to decreased
necrosis and increased fibrotic environment of the
extracellular matrix. Increased levels of inflamma-
tion seen in D2/mdx [3] could also lead to impaired
regeneration.
The use of Student’s t-test to evaluate histologi-
cal data and the tendency to consider histology as a
quantitative measurement are questionable.
In general, it was noted that the picture of disease
progression is not complete for D2/mdx: regener-
ation appears to be reduced in D2/mdx mice and
fibrosis and calcification more prominent, especially
at a young age (<12 weeks). At later time points
the amount of fibrosis and calcification decreases,
showing that regeneration does occur at some time.
Clearly, further analysis is required to clarify the
processes of necrosis, calcification, fibrosis and
regeneration over time.
Miranda Grounds’ group analysed the sciatic
nerves innervating hind limb muscles, based on the
hypothesis that the repeated cycles of myofibre necro-
sis and regeneration with associated disruption of
neuromuscular junctions over many months, may
result in denervation of myofibres with consequent
changes in the sciatic nerve of dystrophic mice (it is
noted that such changes become apparent in older
normal mice after about 15 months of age (12)).
Indeed, for male mice aged 13 months, the Bl10/mdx
mice showed significant signs of denervation (tested
as accumulation of S100 and tau protein in nerves),
whereas this was neither seen in D2/mdx mice, nor
in the wild type strains at this age. The simplest
explanation is that the amount of ongoing necro-
sis of dystrophic muscles was much higher in the
Bl10/mdx, compared with D2/mdx, mice. The new
technology OPT (optical polarization tractography)
allows to reconstruct organization of a whole fiber
and may be useful to look deeper at all histological
aspects, especially in mixed fast/slow muscles like
the tibialis anterior [13, 14].
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BIOMARKERS
D2/mdx mice showed higher inflammation than
Bl10/mdx or wild type strains, as recorded by FACS
analysis for total leucocyte and macrophage popula-
tions, inflammatory foci analysis and Cd68 qPCR,
which decreased over time. The FACS analysis
showed a CD3+ population in both D2/mdx and
DBA/2J wild type at 10 weeks of age, but this popula-
tion disappeared by 30 weeks of age. It was proposed
that neutrophils should be quantified by peroxidase.
Inflammation markers are relevant due to the current
development of anti-inflammatory drugs, however,
differences in mouse and human immune systems
need to be considered, and the inflammatory process
in D2/mdx is not yet fully understood.
Gene expression of fibrosis markers (Tgf, con-
nective tissue growth factor (Ctgf) and collagen) was
increased in mdx compared to wild type and higher
in D2/mdx than in Bl10/mdx, although not as high as
one would expect based on histology. Levels were age
dependent (values decreased in D2/mdx from 10 to 34
weeks) and muscle dependent, the diaphragm being
more affected than the gastrocnemius. As mentioned,
the time course of the fibrotic process, its interac-
tion with calcification and the reason for the decline
of TGF- need to be better clarified in the D2/mdx
mice.
Finally, CK values in blood were somewhat lower
in D2/mdx than in Bl10/mdx, and tend to decrease
with age, as also observed in DMD patients (Fig. 2).
However, the variability is very high, and a range
of sampling methods and protocols were used which
precludes a direct comparison. It was suggested to test
titin fragments in urine (mass-spectrometry, western
blots, antibody stains) as an alternative marker for
muscle pathology.
BEHAVIORAL ACTIVITIES AND
SKELETAL MUSCLE FORCE
MEASUREMENTS
The open field assessment records several param-
eters (total distance travelled, horizontal and vertical
activity, number and time of movements, number of
rearings and resting time) and showed consistent dif-
ferences between mdx and wild type mice in both
strains. However, the total distance travelled and the
number of rearings was lower in D2/mdx than in
Bl10/mdx. This strain-specific difference needs to be
clarified and better assessed over time. Therefore, this
Fig. 2. Creatine kinase values distribution over age in Bl10/mdx
(blue dots), Bl10/wt (red dots), D2/mdx (green dots), D2/wt (black
dots). Data were collected from 4 labs.
assessment remains valuable for longitudinal, proof-
of-concept studies but should be used in combination
with behavioral, physiological and morphological
measures in efficacy studies. The voluntary running
wheel test and the exhaustion test with treadmill run-
ning showed differences in D2/mdx as compared to
wild type, but there are still not enough data to sup-
port strain differences. The hanging wire test showed
similar performances in mdx from both strains but a
certain variability was present that could be partially
explained by gender differences: male mice tend to
perform less well than female mice and would be
preferred in preclinical tests. Behavioral end points
such as the hanging wire test are often influenced
by many variables including sex, handling, time of
testing etc.
As a general conclusion, fatigability tests are con-
sidered disease-relevant, given that in DMD patients,
composite functional clinical readouts, such as 6-
minute walk test or others, are accepted for approval
of therapeutics. There are still a few issues that
need further exploration, such as the progress of per-
formance over time and possible correlations with
reabsorption of calcifications and with fibrosis, the
impact of exercise on pathology progression and the
possible effects of drugs on the central nervous sys-
tem with implications for volition and motivation.
Furthermore, there is a clear need of consensus on
best protocols to be used and on the appropriate
method to acquire data: time-to-event representations
on Kaplan-Meyer diagrams may be more informative
despite individual variability.
Grip strength declined with time for both mdx
mouse strains as compared to wild type. However,
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body weight increased in Bl10/mdx and decreased
in D2/mdx mice over time making normalization to
body weight a matter of debate, since it affects all
normalizations of functional parameters. One option
is to look at changes over time without normalization;
another option, with a good sample size, is to adjust
for the variant body weight and assess the functional
parameter, if the variability is not too high. Therefore,
although being a patient-relevant outcome, the grip
strength is not recommended as primary outcome in
mice, and should instead be used in combination with
more direct muscle physiology assessments. More-
over, despite the high amount of data collected, the
variability between labs and between operators was
extremely high and will always represent an issue
with this measurement. Grip strength remains an
interesting parameter for longitudinal studies in mice,
but ideally should be assessed by a single operator
within an experiment.
Skeletal muscle force can also be measured
directly with three methods: i) In vitro/ex-vivo
method on isolated muscle, that assesses muscle
performance without the interference of neural and
vascular input; ii) In situ terminal method, that main-
tains physiological neural and vascular supply; iii) In
vivo non terminal torque measurements, that record
force from a group of muscles stimulated transder-
mally via the nerve and offers the advantages of
maintaining physiological conditions, being mini-
mally invasive and allowing multiple assessments
in the same animal. For the ex vivo assays (i), mdx
mice were weaker than wild type in both strains, and
D2/mdx tended to be weaker than Bl10/mdx mice.
EDL and diaphragm muscle force can be recom-
mended as primary output, diaphragm data being
useful for respiratory readouts. However, a parallel
comparison of the two strains in the same laboratory
over time is pivotal. For the in situ method (ii) on
tibialis anterior, very limited data were available and
no comparison between strains could be made. For
the in vivo non-terminal torque assessment (iii), no
standardized protocol is available; initial data suggest
that D2/mdx were weaker than age-matched Bl10/
mdx, but longitudinal studies will be needed. In
general, muscle physiology assessments are consid-
ered valid as primary outcomes, they may detect
drug effects that are not morphologically visible.
However, further studies are needed to quantify the
magnitude of strain difference, the age-dependent
variations and the degree and progression of dia-
phragm impairment.
DIAPHRAGM AND RESPIRATORY
PARAMETERS
Data pooling of respiratory function analyses was
impossible due to the diversity in protocols used. In
D2/mdx mice, the pulmonary function was reduced
but the response to CO2 challenge was not as strong
as seen with Bl10/mdx mice, if the reduced weight
of the D2/mdx strain was not accounted for. If the
data were normalized, or if mice were tested at
32 weeks of age, this difference disappeared. This
decline in function is relevant to DMD patients.
However, the strain related differences need to be
established. As described before, specific diaphragm
force, measured by ex vivo analyses, decreased with
age in Bl10/mdx and the drop in force was compa-
rable in D2/mdx mice. This outcome is measured
post-mortem and has a limited translatability, but
is considered reproducible if standardized protocols
are used.
The fibrosis and calcification of the diaphragm
observed in D2/mdx mice were extensive and more
pronounced than in other muscles: however, as in
other muscles, the calcification decreased with age.
CARDIAC PARAMETERS
The most clinically relevant measurement on car-
diac function is the shortening fraction, assessed by
echocardiography in mice and patients; for mice,
good standardized protocols (SOP: standardized
operating procedure) exist and variability is small
if these are followed. The ejection fraction is more
difficult to measure clinically and in mice is a less
reliable measure, most often calculated from M-mode
measures [15, 16]. As measured using the TREAT-
NMD/PPMD SOPs [17, 18], the shortening fraction
was lower in D2/mdx than in its wild type counter-
part aged 16–28 weeks, and this is normally seen in
Bl10/mdx aged 36 to 52 weeks. However, the shorten-
ing fraction increased to normal levels at 52 weeks in
the D2/mdx model [3]. The reason for this improve-
ment in D2/mdx mice needs to be further elucidated,
possibly heart wall thickness plays a role. Cardiac
magnetic resonance (CMR) imaging was also used in
the cardiac assessment of D2/mdx mice and demon-
strated decreased function at 28 weeks of age [19].
Based on these measures, a mild cardiomyopathy
occurs earlier in the D2/mdx compared to Bl10/mdx
mice.
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Other cardiac functional measures are: pres-
sure/volume loops, (cardiac catheter assay) and ECG.
The heart rate is increased in both mdx strains as
compared to their wild type controls and is seen in
patients with DMD. Fibrosis was evident in hearts
of D2/mdx mice, as early at 8 weeks of age and, as
expected, calcification was high in the 10-weeks-old
heart of both mdx and wild type on DBA background,
but absent on the Bl10 background. The etiology
and significance of cardiac calcifications require fur-
ther study. In summary, histological and biochemical
assessments of fibrosis are recommended, but best
methods need to be chosen. If possible, fibrosis quan-
tification should be aligned with biomarkers or CMR
of cardiac function or measurements of myocardial
composition [19].
THERAPEUTIC INTERVENTIONS
In general, the D2/mdx mouse offers either a larger
or smaller observational window to test effects of
therapeutic interventions depending on the type of
readout chosen. Therefore, which model is most rel-
evant will differ based on the intervention that is
studied.
Thus far, limited data are available on therapeutic
interventions tested in the D2/mdx mouse model [20,
21]. A small pilot was performed comparing treat-
ment with antisense oligonucleotides in D2/mdx and
Bl10/mdx mice. There was no difference between
Bl10/mdx and D2/mdx mice in exon skipping effi-
ciency, suggesting that this model is suitable for
future studies.
Natural history data are incomplete, the pathophys-
iology at early ages and the course of the processes
of necrosis, regeneration, calcification and fibrosis
need to be elucidated, which for now hampers design-
ing optimal therapeutic intervention studies in the
D2/mdx model. Such preclinical therapeutic studies
should be run in parallel with vehicle-treated con-
trols, and with a choice of outcomes not affected
by intrinsic or operator-derived variability. Ideally,
studies should be conducted in two independent labs.
Treatments tested should target different pathways
(for instance inflammation, muscle mass growth, dys-
trophin restoration, etc.).
RECOMMENDATIONS
From our efforts some points can be summarized:
1) Most reliable outcomes are muscle specific force
measures and open field; outcomes with caveats are
grip strength and mouse fatigability, fibrosis and
whole-body plethysmography with CO2 challenge,
cardiac outcomes; caution is needed with assays such
as CK in blood and histological central nucleation. 2)
Experimental conditions, especially mouse gender,
power size per outcome, ages, vehicle use, best pro-
tocol but also husbandry and timing of measurements
should be defined. 3) Blinded assessment is recom-
mended especially when testing therapeutics in mice
of the same genotype (undistinguishable by eyes) and
especially for those methodologies which require a
subjective role of the experimenter (i.e., behavioural
tests, hand-made histology analysis, etc.). Addition-
ally, data groups can be blinded for the statistical
analysis. Existing TREAT-NMD standardized oper-
ating procedures can be selected and extended to the
D2/mdx mouse model, others may need to be drafted
ex novo.
It is recognized that a robust natural history data
collection should represent a key achievement prior
to testing therapies, and an appropriate location for a
sharable database should be identified. In particular,
more detailed longitudinal studies on the courses of
necrosis/regeneration, calcification and fibrosis over
time are needed; time points for histological data col-
lection should be agreed upon (suggested: 2 wk, 4 wk,
6 wk, 12 wk, 6 mo, 1 year); cardiac pathology needs
to be followed up after 24 weeks. For biomarkers, it
seems more practical to choose clinically validated
markers and test their preclinical translatability fol-
lowing treatment in mice. Furthermore, a minimum
of criteria that need to be met for proof-of-concept
versus preclinical studies should be defined.
As next steps, the following priorities were iden-
tified for the field and will be considered by the
Organizing Committee. First, the existing TREAT-
NMD SOPs need to be reviewed to assess their
suitability for D2/mdx analysis and, if suitable,
D2/mdx data need to be integrated. SOPs currently
missing should be identified, and working groups to
generate them should be established. Second, for the
outcome measures identified as usable and reliable,
data gaps should be filled. Ideally, the data should
be collected in a concerted and independent experi-
mental effort of laboratories using standardized and
complementary approaches. Interested stakeholders
will be needed for funding to support this time- and
resource-intensive action. Such an effort will help to
enable the compilation of a natural history database
that hosts datasets for D2/mdx and Bl10/mdx mice to
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benefit the scientific community (both academic and
private) interested in translational research in DMD.
Finally, considering the fact that even these expert
groups collected data for outcomes in different ways,
it is clear that the field needs to reach consensus on
which outcomes to select and how to assess them. A
white paper is under discussion to identify and define
the best practices.
ACKNOWLEDGMENTS
A special thanks to the Scientific Organizing
Committee: Annemieke Aartsma-Rus, Annamaria
De Luca, Heather Gordish-Dressman, Kanneboyina
Nagaraju, Melissa Spencer, Maaike van Putten, and
Laura Dalle Pazze and Arati Kreibich of Charley’s
Fund for the coordination of all efforts before and
during the workshop.
The workshop was sponsored by Charley’s Fund
in collaboration with the TREAT-NMD Alliance.
Dr. Nagaraju is supported by National Institutes of
Health grants # K26OD011171. Dongsheng Duan is
supported by NIH (AR67985, AR69085, NS90634),
DOD (MD150133), Jesse’s Journey, Jackson Freel
DMD Research Fund and Solid Biosciences.
DISCLOSURES
Dongsheng Duan is a member of the scientific
advisory board for Solid Biosciences and an equity
holder of Solid Biosciences. The Duan lab has
received research support from Solid Biosciences.
Annamaria De Luca has provided ad hoc consul-
tancy in 2017 to Akashi Therapeutics and Gru¨nenthal
GmbH. Frederick J. Schnell and Marco A. Passini
are paid employees of Sarepta Therapeutics Inc. Lau-
rent Bogdanik and Cathleen Lutz are paid employees
of The Jackson Laboratory. David Elsey is a paid
employee of Summit Therapeutics plc. Mahasweta
Girgenrath is a paid employee of Pfizer Inc. J. Patrick
Gonzalez is a paid employee of Solid Biosciences.
Andy Nichols is a paid employee of Catabasis Phar-
maceuticals Inc. Zhong Zhong is a paid employee
of Wave Life Sciences Ltd. Toshifumi Yokota has
provided ad hoc consultancy in 2018 to Agada Bio-
sciences.
REFERENCES
[1] Bulfield G, Siller WG, Wight PA, Moore KJ. X
chromosome-linked muscular dystrophy (mdx) in the
mouse. Proc Natl Acad Sci U S A. 1984;81(4):1189-92.
[2] Fukada S, Morikawa D, Yamamoto Y, Yoshida T, Sumie
N, Yamaguchi M, et al. Genetic background affects prop-
erties of satellite cells and mdx phenotypes. Am J Pathol.
2010;176(5):2414-24.
[3] Coley WD, Bogdanik L, Vila MC, Yu Q, Van Der Meulen
JH, Rayavarapu S, et al. Effect of genetic background on
the dystrophic phenotype in mdx mice. Hum Mol Genet.
2016;25(1):130-45.
[4] Heydemann A, Ceco E, Lim JE, Hadhazy M, Ryder P,
Moran JL, et al. Latent TGF-beta-binding protein 4 modifies
muscular dystrophy in mice. J Clin Invest. 2009;119(12):
3703-12.
[5] Swaggart KA, Demonbreun AR, Vo AH, Swanson KE, Kim
EY, Fahrenbach JP, et al. Annexin A6 modifies muscular
dystrophy by mediating sarcolemmal repair. Proc Natl Acad
Sci U S A. 2014;111(16):6004-9.
[6] Swaggart KA, McNally EM. Modifiers of heart and muscle
function: Where genetics meets physiology. Exp Physiol.
2014;99(4):621-6.
[7] Quattrocelli M, Capote J, Ohiri JC, Warner JL, Vo AH, Ear-
ley JU, et al. Genetic modifiers of muscular dystrophy act
on sarcolemmal resealing and recovery from injury. PLoS
Genet. 2017;13(10):e1007070.
[8] Flanigan KM, Ceco E, Lamar KM, Kaminoh Y, Dunn DM,
Mendell JR, et al. LTBP4 genotype predicts age of ambu-
latory loss in Duchenne muscular dystrophy. Ann Neurol.
2013;73(4):481-8.
[9] McGreevy JW, Hakim CH, McIntosh MA, Duan D. Ani-
mal models of Duchenne muscular dystrophy: From basic
mechanisms to gene therapy. Dis Model Mech. 2015;8(3):
195-213.
[10] Hathout Y, Brody E, Clemens PR, Cripe L, DeLisle RK,
Furlong P, et al. Large-scale serum protein biomarker dis-
covery in Duchenne muscular dystrophy. Proc Natl Acad
Sci U S A. 2015;112(23):7153-8.
[11] Rodrigues M, Echigoya Y, Maruyama R, Lim KR, Fukada
SI, Yokota T. Impaired regenerative capacity and lower
revertant fibre expansion in dystrophin-deficient mdx mus-
cles on DBA/2 background. Sci Rep. 2016;6:38371.
[12] Krishnan VS, White Z, McMahon CD, Hodgetts SI, Fitzger-
ald M, Shavlakadze T, et al. A Neurogenic Perspective
of Sarcopenia: Time Course Study of Sciatic Nerves
From Aging Mice. J Neuropathol Exp Neurol. 2016;75(5):
464-78.
[13] Wang Y, Zhang K, Wasala NB, Duan D, Yao G. Optical
polarization tractography revealed significant fiber disarray
in skeletal muscles of a mouse model for Duchenne muscu-
lar dystrophy. Biomed Opt Express. 2015;6(2):347-52.
[14] Wang Y, Zhang K, Duan D, Yao G. Heart structural remodel-
ing in a mouse model of Duchenne cardiomyopathy revealed
using optical polarization tractography [Invited]. Biomed
Opt Express. 2017;8(3):1271-6.
[15] Spurney CF, McCaffrey FM, Cnaan A, Morgenroth LP,
Ghelani SJ, Gordish-Dressman H, et al. Feasibility and
Reproducibility of Echocardiographic Measures in Chil-
dren with Muscular Dystrophies. J Am Soc Echocardiogr.
2015;28(8):999-1008.
[16] Soslow JH, Xu M, Slaughter JC, Stanley M, Crum K,
Markham LW, et al. Evaluation of Echocardiographic Mea-
sures of Left Ventricular Function in Patients with Duchenne
Muscular Dystrophy: Assessment of Reproducibility and
Comparison to Cardiac Magnetic Resonance Imaging. J Am
Soc Echocardiogr. 2016;29(10):983-91.
[17] Available from: http://www.treat-nmd.eu/research/preclini
cal/dmd-sops.
H. Gordish-Dressman et al. / Advance Duchenne Muscular Dystrophy Therapies 417
[18] Duan D, Rafael-Fortney JA, Blain A, Kass DA, McNally
EM, Metzger JM, et al. Standard Operating Procedures
(SOPs) for Evaluating the Heart in Preclinical Studies of
Duchenne Muscular Dystrophy. J Cardiovasc Transl Res.
2016;9(1):85-6.
[19] Vohra R, Batra A, Forbes SC, Vandenborne K, Walter GA.
Magnetic Resonance Monitoring of Disease Progression in
mdx Mice on Different Genetic Backgrounds. Am J Pathol.
2017;187(9):2060-70.
[20] Ito T, Ogawa R, Uezumi A, Ohtani T, Watanabe Y, Tsu-
jikawa K, et al. Imatinib attenuates severe mouse dystrophy
and inhibits proliferation and fibrosis-marker expression
in muscle mesenchymal progenitors. Neuromuscul Disord.
2013;23(4):349-56.
[21] Takemoto Y, Inaba S, Zhang L, Baba K, Hagihara K, Fukada
S. An herbal medicine, Go-sha-jinki-gan (GJG), increases
muscle weight in severe muscle dystrophy model mice.
Clinical Nutrition Experimental. 2017;16:13-23.
